Literature DB >> 17894648

Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent.

Pierre Etienne Chabrier1, Michel Auguet.   

Abstract

BN82451 belongs to a new family of small molecules designated as multitargeting or hybrid molecules. BN82451 is orally active, has good central nervous system penetration, and elicits potent neuronal protection and antiinflammatory properties. Neuronal protection is due to Na+ channel blockade, antioxidant properties, and mitochondria-protecting activity, whereas inhibition of cyclooxygenases is mostly responsible for its antiinflammatory activity. BN82451 has been shown to exert a potent neuroprotective effect in various in vitro and in vivo animal models. BN82451 was found to exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis. Collectively, its pharmacological properties designate BN82451 as a promising neuroprotective agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894648      PMCID: PMC6494126          DOI: 10.1111/j.1527-3458.2007.00018.x

Source DB:  PubMed          Journal:  CNS Drug Rev        ISSN: 1080-563X


  3 in total

Review 1.  Redox Signaling by Reactive Electrophiles and Oxidants.

Authors:  Saba Parvez; Marcus J C Long; Jesse R Poganik; Yimon Aye
Journal:  Chem Rev       Date:  2018-08-27       Impact factor: 60.622

Review 2.  Novel targets for Huntington's disease: future prospects.

Authors:  Sarah L Mason; Roger A Barker
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-05-04

3.  IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.

Authors:  Romina Aron Badin; Brigitte Spinnewyn; Marie-Claude Gaillard; Caroline Jan; Carole Malgorn; Nadja Van Camp; Frédéric Dollé; Martine Guillermier; Sabrina Boulet; Anne Bertrand; Marc Savasta; Michel Auguet; Emmanuel Brouillet; Pierre-Etienne Chabrier; Philippe Hantraye
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.